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Abstract 
Introduction: Walking exercise is a recommended but underused treatment for 
intermittent claudication caused by peripheral arterial disease (PAD). Addressing the 
factors that influence walking exercise may increase patient uptake of and adherence to 
recommended walking. The primary aim of this randomised controlled trial (RCT) is to 
evaluate the efficacy of a physiotherapist-led behaviour change intervention on walking 
ability in adults with intermittent claudication (MOtivating Structured walking Activity 
in Intermittent Claudication (MOSAIC)) in comparison with usual care. 
Methods and analysis: The MOSAIC trial is a two-arm, parallel-group, single-blind RCT. 
192 adults will be recruited from six National Health Service Hospital Trusts. Inclusion 
criteria are: aged ≥50 years, PAD (Ankle Brachial Pressure Index ≤0.90, radiographic 
evidence, or clinician report) and intermittent claudication (San Diego Claudication 
Questionnaire), being able and willing to participate and provide informed consent. The 
primary outcome is walking ability (6-Minute Walking Distance) at three months. 
Outcomes will be obtained at baseline, three and six months by an assessor blind to 
group allocation. Participants will be individually randomised (n=96/group, stratified 
by centre) to receive either MOSAIC or usual care by an independent randomisation 
service. Estimates of treatment effects will use an intention-to-treat framework 
implemented using multiple regression adjusted for baseline values and centre.  
Ethics and dissemination: This trial has full ethical approval (London - Bloomsbury 
Research Ethics Committee (17/LO/0568)). It will be disseminated via patient forums, 
peer-reviewed publications and conference presentations.  
Registration: ISRCTN 14501418. Pre-results. 
Strengths and limitations of this study: 
•This is the first trial to investigate the efficacy of a physiotherapist-led behaviour 
change intervention on walking ability in people with intermittent claudication. 
•This trial collects validated objective and self-reported outcomes of walking ability.  
•Clinician’s experiences of training and delivering MOSAIC and intervention fidelity will 
be explored to inform implementation into practice.  
•This trial only follows participants for six months post randomisation 
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Introduction 
Background and objectives 
Walking exercise is an effective treatment for intermittent claudication (1), an 
ischaemic leg pain caused by peripheral arterial disease (PAD). It improves walking 
distances and duration compared to usual National Health Service (NHS) treatment (2) 
or pharmaceutical therapy (3) and has comparable long-term outcomes to 
revascularisation (4, 5). The Trans-Atlantic Inter-Society Consensus-II Group 
recommend supervised walking exercise at an intensity that induces pain within 3–5 
minutes, for 30–60 minutes/session conducted three times/week for three months (6). 
Similarly, the National Institute for Health and Care Excellence recommends two hours 
of supervised exercise/week for three months (7). However, guideline implementation 
is poor (8-10) and, even when supervised exercise therapy is available, patient uptake 
and adherence is variable  (11). Consequently usual care for most individuals with 
intermittent claudication is simple walking advice, however, despite advice, self-
directed walking is frequently overlooked as a management strategy (12),  participation 
is low (10, 13) and often ineffective (14).  
Adopting and maintaining a new health behaviour, such as walking exercise, is 
challenging and people with intermittent claudication frequently do not achieve walking 
recommendations (11, 15, 16). Barriers to walking exercise in people with intermittent 
claudication  include the need to stop and rest to alleviate pain, the impact of undulating 
terrain and a lack of clarity around the recommendations for walking (13, 17). These 
challenges can be difficult to overcome without appropriate guidance and support.  
Structured home‐based exercise programmes may offer a promising alternative to 
supervised exercise therapy (18, 19). These programmes typically include exercise 
sessions completed away from a healthcare facility with support from healthcare 
professionals and may overcome the barriers of accessibility and availability (14, 18, 
20). Evidence from  recent systematic reviews suggests that structured home exercise 
may improve walking performance although the quality of the included trial is mixed 
and few studies evaluate systematically developed interventions which incorporate 
theoretically-informed strategies to facilitate the uptake and long-term adherence to 
walking exercise (14, 20). 
Crucial conditions to support health behaviour change, such as increasing self-directed 
walking exercise, are an individual’s capability (e.g. knowledge and understanding that 
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walking exercise is a treatment for intermittent claudication), opportunity (e.g. 
identifying an appropriate environment place to walk) and motivation (e.g. attitudes 
and beliefs about walking as a treatment) (21-23). Evidence suggests that targeting 
these factors using behaviour-change techniques (e.g. setting walking goals, action 
planning (22, 24) or motivational interviewing (25)) in addition to exercise or advice 
may increase walking ability in people with intermittent claudication (24, 26).  
Motivating Structured walking Activity in people with Intermittent Claudication 
(MOSAIC) is a structured, physiotherapist-led behaviour-change intervention which 
aims to increase walking in people with intermittent claudication. It is informed by two 
psychological models  i) The Theory of Planned Behaviour (27, 28) and ii) The 
Common-Sense Model of Illness Representations (29, 30). The Theory of Planned 
Behaviour proposes that people use information (e.g. social, personal and 
environmental conditions) around them to make decisions about whether to perform a 
behaviour (e.g., walking exercise) (27, 28). Interventions underpinned by the Theory of 
Planned Behaviour have shown utility in physical activity behaviour change (31), and 
the socio-cognitive factors defined by this model are associated with motivation to walk 
and walking ability in adults with intermittent claudication (23, 32). The Common-
Sense Model of Illness Representations proposes that individuals form personal, lay 
explanations of their illness (e.g. PAD) and symptoms (e.g. intermittent claudication), 
which guides how they manage their condition and seek treatment (29, 30). The 
Common-Sense Model has been instrumental in understanding how people cope with 
long-term illness (33). Illness perceptions defined by the Common Sense Model, 
including beliefs about PAD, its causes and one’s ability to control or manage the 
condition and symptoms, are associated with walking ability in people with intermittent 
claudication (23). 
MOSAIC was systematically developed to target the salient factors identified from these 
two models (12, 23) and includes behaviour change techniques to facilitate the uptake 
and maintenance of walking exercise (24). This protocol was informed by a preliminary 
study which demonstrated that the MOSAIC intervention and trial procedures were 
acceptable to participants and clinicians and feasible to deliver (26).  
 
Objectives  
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The primary objective is to answer the question: Does MOSAIC improve walking ability 
(measured by the 6 Minute Walking Distance [6MWD]) at the primary end-point of 
three months compared to usual care in older adults with intermittent claudication? 
  
The secondary objectives include answering the questions: 
1) Does MOSAIC improve a) activities of daily living and quality of life [QoL] at three 
months; and b) walking ability, activities of daily living and QoL at six months compared 
to usual care in older adults with intermittent claudication?  
2) Is it feasible to collect resource use data using a modified measure in older adults 
with intermittent claudication?  
3) What are the Minimal Clinically Important Difference (MCID) values for the clinical 
assessments used for older adults with intermittent claudication? 
 
Methods 
Trial Design 
A phase II, prospective, assessor blinded, multi-centre, parallel group, two-arm, 
randomised, controlled superiority trial with nested qualitative study (Figure 1). 
 
Participant Eligibility Criteria 
Individuals will be eligible for the trial if they meet the following inclusion criteria: 
a) adults ≥50 years of age;  
b) established PAD (determined by either Ankle Brachial Pressure Index ≤0.90, 
radiographic evidence or clinician report) and intermittent claudication (reported on 
the San Diego Claudication Questionnaire (34));  
c) able and willing to participate in MOSAIC and provide informed consent.  
 
Individuals may not enter the study if they meet the following exclusion criteria: 
a) unstable intermittent claudication (e.g., self-reported change in symptoms during 
previous three months in response to the question ‘ have your symptoms changed in the 
last 3 months?);  
b) walking >90 minutes/week (reported on the Brief International Physical Activity 
Questionnaire (IPAQ) (35));  
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c) contraindications to walking exercise (e.g., unstable angina) confirmed by the direct 
care team;  
d) have completed any prescribed supervised exercise sessions in the previous six 
months or been offered prescribed supervised exercise sessions in the next six months. 
 
Setting 
Participants will be recruited from five NHS Foundation Trusts in London (Guy’s and St 
Thomas’, King’s College, St George’s, Royal Free, Royal London) and one in the South 
East of England (Ashford and St Peter’s), UK. The MOSAIC intervention is delivered 
either at the participants’ home or a private room in the participating site to allow 
flexibility, inclusivity and confidentiality, while minimising contamination. 
 
Interventions 
Motivating Structured walking Activity in people with Intermittent Claudication 
(MOSAIC) 
Participants randomised to the intervention group will receive the MOSAIC intervention 
in addition to the usual care provided by their direct care team. 
 
MOSAIC aims to increase an individual’s walking ability. It comprises two 60-minute 
face-to-face consultations (weeks 1 & 2) and two 20-minute follow-up telephone calls 
(weeks 6 & 12). The content of each session is standardised and incorporates 15 
behaviour change techniques, but sessions may be tailored based on participants’ 
knowledge, goals, symptoms, and current walking (Table 1 and 2). Walking plans will be 
agreed collaboratively between the participant and the physiotherapist and include 
progressive, individualised targets for walking frequency, intensity and duration to 
achieve recommendations (30-50 minutes of walking 3 times/week at an intensity that 
elicits pain within 3-5 minutes) (6). MOSAIC is supplemented by an interactive 
participant manual, containing worksheets and a walking diary, and by a pedometer.  
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Table 1 Format and content of the MOtivating Structured walking Activity in people with Intermittent 
Claudication (MOSAIC) intervention 
1. Session 1 (60-minute face-to-face) 2. Session 2 (60-minute face-to-face) 
Establish mutual objectives for session. Identify 
participant expectations, reframe unrealistic 
expectations, summarise format and how 
MOSAIC might be helpful. 
Elicit participant experiences and understanding 
of their disease/ symptoms. With permission, 
provide relevant information). 
Elicit treatment experiences. Discuss any 
treatment the participant has attempted and 
introduce walking as an option.  
With permission, provide further information 
about walking as treatment and elicit the 
participant’s thoughts on this information. 
With permission, provide standard walking 
recommendations for intermittent claudication.  
Invite participant thoughts on this new 
information, provide reassurance, if needed. 
Introduce participant manual, highlighting the 
key information a participant may wish to 
review and consider before next session. 
Establish mutual objectives for session.  Review 
session 1 & confirm / reframe participant 
expectations, as required. 
Evoke discussion about participant’s current 
walking, reinforcing change talk by affirming 
positive efforts and successes. 
Elicit or reinforce change talk, supporting 
increased readiness to walk and addressing any 
signs of uncertainty.  
Shift focus to mobilisation and commitment to 
change.  
Introduce goal setting and discuss role of 
walking exercise in achieving valued activities 
(e.g., hobbies); agree a goal to increase walking.  
Introduce action planning and agree and record 
a tailored exercise prescription and walking 
Action Plan in the participant manual.  
Address problem solving Identify potential 
barriers to goals and measures for overcoming 
anticipated or unexpected obstacles using 
participant manual. 
Introduce self-monitoring and provide walking 
self-monitoring tools. Elicit participant interest 
in and confidence to use these tools.  
3. Session 3 (20-minute telephone call) 4. Session 4 (20-minute telephone call) 
Review of previous sessions and establish 
mutual objectives for telephone call.  
Review and provide feedback on progress 
toward goals using the goal setting sheet, 
affirm positive attempts and efforts.   
Elicit discussion and reflection on self-
monitoring skills. Affirm efforts to self-monitor. 
Problem solve new issues by eliciting reflection 
on anticipated and actual barriers and problem 
solve collaboratively.  
Review and accept or revise walking goals and 
action plans, as necessary. 
Support maintenance: discuss and define 
relapse. Discuss any new barriers and 
measures to overcome these and identify 
strategies to re-engage. 
Generalise skills and behaviour: discuss ways 
that walking can be incorporated to daily life. 
Elicit discussion on how skills can be applied to 
new health goals. 
Review of previous sessions and establish mutual 
objectives for telephone call.  
Review and provide feedback on progress 
toward goals using the goal setting sheet, affirm 
positive attempts and efforts.   
Elicit discussion and reflection on self-
monitoring skills. Affirm efforts to self-monitor. 
Problem solve new issues by eliciting reflection 
on anticipated and actual barriers and problem 
solve collaboratively. 
Review and accept or revise walking goals, as 
necessary. 
Discuss and revise goals and action plan, as 
necessary. 
Support maintenance: Discuss any new barriers 
and measures to overcome these and identify 
strategies to re-engage. 
Generalise skills and behaviour: discuss how 
walking can be incorporated to daily life. 
Elicit discussion on how skills can be applied 
to new health goals. Signpost to community 
resources. 
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Table 2. Behaviour Change Techniques included in MOtivating Structured walking Activity in people with 
Intermittent Claudication (MOSAIC) intervention 
Behaviour Change 
Technique 
Definition  
Delivery of Behaviour 
Change Technique 
Example of Mapped 
Construct from the 
TPB or CSM 
Social support 
(general) 
Advise on, arrange, or 
provide social support, 
or non-contingent 
praise or reward for 
performance of the 
behaviour, and 
encouragement and 
counselling when 
directed at the 
behaviour (e.g., 
motivational 
interviewing) 
Physiotherapist trained in 
motivational interviewing, 
values-based goals elicited 
to support autonomy, 
change talk facilitated 
through patient-centred 
dialogue 
Subjective Norm (TPB) 
and the personal 
schematic illness 
representation (CSM)  
Information about 
health 
consequences  
Provide information 
about health 
consequences of 
performing the 
behaviour  
Potential benefits of 
walking discussed, 
including ability to walk 
further before pain onset 
or need to stop and rest.  
Attitude (TPB), 
Treatment control 
(CSM)  
Reduce negative 
emotions 
Advise on ways of 
reducing negative 
emotions to facilitate 
performance of the 
behaviour 
Elicit and address worry or 
fear about walking, 
assuring participant that 
IC is not a sign of damage 
to the limb, if required 
Emotional response 
(CSM), Attitude (TPB) 
Framing/reframing  Suggest the deliberate 
adoption of a 
perspective or new 
perspective on 
behaviour (e.g. its 
purpose) to change 
cognitions or emotions 
about performing the 
behaviour 
If the participant reports a 
belief about walking which 
is not consistent with 
evidence review the topic 
and suggest alternatives 
to the participant to 
support their 
understanding 
Attitude (TPB) and 
Coherence (CSM) 
Focus on past 
success 
Advise to think about 
or list previous 
successes in 
performing or 
attempting the 
behaviour 
Highlight and reinforce 
successful attempts at 
walking (or other health 
behaviour if no walking 
attempted), even if goals 
are not fully achieved 
Perceived Behavioural 
Control (TPB) 
Goal setting 
(behaviour) 
Set or agree on a goal 
defined in terms of the 
behaviour to be 
achieved 
Walking goal defined in 
terms of frequency, 
duration, intensity, and 
context. Based on current 
walking with the aim of 
progressing toward 
recommended walking 
level  
Intention (TPB) 
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Goal setting 
(outcome) 
Set or agree on a goal 
defined in terms of a 
positive outcome of 
wanted behaviour 
Value-based goal 
identified which would be 
facilitated by improved 
walking (e.g., work, hobby, 
social activity) 
Intention (TPB) 
Instruction on how 
to perform 
behaviour 
Advise or agree on 
how to perform the 
behaviour (walking) 
Discuss the walking 
recommendations with 
the participant  
Treatment control 
(CSM), Attitude (TPB) 
Problem solving Analyse or prompt 
analysis of factors 
influencing the 
behaviour and 
generate or select 
strategies that include 
overcoming barriers 
and / or increasing 
facilitators 
Participants encouraged 
to identify barriers which 
may prevent them 
achieving their goal, and 
realistic solutions 
discussed and agreed 
Perceived behavioural 
control (TPB) 
Action planning Prompt detailed 
planning of behaviour 
performance, including 
at least one of: 
context, frequency, 
duration, or intensity 
Action plan worksheet 
completed, recording 
details of the context, 
frequency, duration and 
intensity of walking goal 
Intention-Behaviour 
Translation (TPB) 
Self-monitoring of 
behaviour 
Establish a method for 
the person to monitor 
or record their 
behaviour as part of a 
behaviour-change 
strategy 
Physiotherapist discussed 
methods to monitor daily 
walking (e.g., wearing a 
watch, or using landmarks 
to note distance achieved) 
Self-Regulation (CSM) 
and Intention-
Behaviour Translation 
(TPB) 
Review 
behavioural goals 
Review behavioural 
goals jointly and 
consider modifying 
goal or behaviour-
change strategy in light 
of achievement  
Walking discussed relative 
to goals and revised as 
appropriate to be more 
achievable or challenging  
Self-Regulation (CSM) 
and Intention-
Behaviour Translation 
(TPB) 
Review outcome 
goals 
Review outcome goals 
jointly and consider 
modifying goals in light 
of achievement 
Value-based goal 
considered relative to 
walking and revised if no 
longer salient 
Self-Regulation (CSM) 
and Intention-
Behaviour Translation 
(TPB) 
Feedback on 
behaviour 
Monitor and provide 
informative or 
evaluative feedback on 
performance of the 
behaviour 
Walking completed by 
participant is discussed 
considering individual 
goals and recommended 
walking treatment for IC 
Self-Regulation (CSM) 
and Intention-
Behaviour Translation 
(TPB) 
Generalisation of a 
target behaviour 
Advise to perform the 
wanted behaviour, 
which is already 
performed in a 
particular situation, in 
another situation 
Together, identify ways 
that walking can be 
incorporated to daily life 
in a way that will maintain 
or improve IC. 
Personal control 
(CSM), Perceived 
behavioural control 
CSM, Common Sense Model of Illness Representations; TPB, Theory of Planned Behaviour. 
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Physiotherapist training and supervision 
The MOSAIC sessions will be delivered by experienced physiotherapists (Band 6 and 
above) who will be trained in Motivational Interviewing and behaviour change 
techniques. All trial physiotherapists will receive two days training on the trial 
objectives, research processes, underpinning psychological theories and MOSAIC 
intervention content, delivery and materials. Trial physiotherapists will be explicitly 
instructed on how to identify and report any adverse events and about the risks and 
consequences of contamination. Training will be delivered by the trial team (LB, JW, MGH, 
JB, GF, BV) and an accredited provider of Motivational interviewing training (Pip Mason 
Consultancy). A bespoke manual will support training and delivery of MOSAIC and 
includes an intervention checklist for each session. 
 
To promote consistency of intervention delivery, all face-to-face and telephone sessions will 
be audio-recorded and individualised feedback on at least one of the first face-to-face and 
telephone MOSAIC sessions will be provided to each physiotherapist by a member of the 
trial team (LB, BV). Physiotherapists will record each session on a checklist (e.g. duration, 
content) which will be reviewed by members of the trial team for adherence to the 
intervention. The trial physiotherapists will attend regular meetings supervised by 
members of the trial team (JW, LB, BV) to maintain skills and receive feedback and support. 
 
Usual care comparison 
Participants randomised to the comparison group will continue to receive usual care 
provided by the NHS for intermittent claudication. Usual care is typically delivered in 
the vascular outpatient clinic by a vascular surgeon or specialist nurse and may include: 
the provision of information about PAD and lifestyle modifications (e.g. smoking 
cessation, diet, weight management), supervised exercise, risk factor management 
including lipid modification, statin therapy and antiplatelet therapy, pharmacotherapy 
to improve leg function (vasodilators such as Naftidrofuryl oxalate) or revascularization 
(e.g. angioplasty, stenting, bypass) (7). Participants may seek concomitant treatment 
during the trial if they wish to. Any other treatments accessed by participants, (e.g. from 
their General Practitioner/ other health professionals), will be recorded on a modified 
Client Service Receipt Inventory (36) at follow-up. 
 
Participant identification and recruitment  
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Potentially eligible patients will be identified by one of two methods which will proceed 
in parallel: 
(a) Patients will be approached by the direct care team during routine clinical 
appointments at participating sites. Potential participants will be provided with an 
explanation of the trial, an invitation letter and participant information sheet and, if 
interested, asked to provide permission to be contacted by the study recruitment 
personnel.  
(b) Patients will be identified from existing clinical lists/databases (depending on 
availability of these at participating sites) and will be sent an invitation pack including: 
an invitation letter, participant information sheet, consent to be contacted form and 
pre-paid return envelope. Non-responders will be contacted by telephone 
approximately four weeks later.  
 
Patients expressing an interest in participating in the trial will be contacted by the study 
recruitment personnel to complete full eligibility screening. Eligible patients who do not 
wish to take part in the trial will be asked if their age and gender may be recorded and if 
they wish to provide a reason for opting not to participate.  
Eligible patients will be invited to attend an appointment at their participating site to 
provide written informed consent and complete a baseline assessment.  
 
Randomisation, blinding and allocation concealment  
Outcome measures will be collected by an independent assessor who will attend each 
site and will be masked to group allocation. The independent assessor will not be 
involved in delivering MOSAIC.  
Following baseline data collection, the independent assessor will notify a web-based 
randomisation service to randomise each participant. The randomisation service is 
provided by the UK Clinical Research Collaboration Registered King’s Clinical Trials Unit 
and will ensure prospective registration and allocation concealment. Randomisation 
will be at the level of the individual, using block randomisation with randomly varying 
block sizes, stratified by centre. The online randomisation system will generate emails 
automatically to delegated members of the research team and the allocating trial 
physiotherapists at the study sites. The allocating trial physiotherapists will coordinate 
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the delivery of MOSAIC at the study site but will not share this information with the 
independent assessor.    
The recruiting personnel and independent assessor are masked to group allocation. The 
trial statistician, the research staff undertaking the qualitative study, the participants 
and the trial physiotherapists are not masked to group allocation. 
 
Outcome Assessment 
Measures will be conducted immediately before randomisation (baseline), and at three 
months and six months post-randomisation (Table 3). 
 
Data collection 
Written informed consent will be obtained prior to any data collection. Baseline and 
three-month follow-up measures will be conducted face-to-face by an independent 
assessor who will attend each site. At six months, the outcomes will be collected either 
electronically or via a standard postal questionnaire pack (with pre-paid return 
envelope). 
Data will be collected and stored using a secure database system. Participants opting to 
complete self-reported assessments electronically will be provided a unique username 
and password to log onto the database and complete measures either during the face-
to-face appointment (baseline and three-months) or from home (at six-months). Any 
research data completed by pencil and paper will be entered to the secure database by 
the independent outcome assessor or trial research assistant. 
At three-month follow up, participants who are unable or refuse to attend an 
appointment to complete the primary outcome will be invited to complete the 
secondary outcomes at home either electronically or by post.  
Attrition will be minimised via standardised text, email and telephone reminders. 
Following these, if no data has been returned, the assessor will telephone the 
participant to collect a minimum data set (Table 3). 
 
Baseline measures 
At baseline, participants will complete a bespoke sociodemographic and clinical 
characteristics questionnaire (including age, sex, smoking history, co-morbidities and 
claudication symptom classification (San Diego Claudication Questionnaire (34)). 
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Standard measures of Body Mass Index and Ankle-Brachial Pressure Index (37) will also 
be determined in addition to the outcomes detailed below.  
 
Primary outcome 
The primary outcome is the difference in mean 6 Minute Walking Distance (6MWD in 
metres) at three months between groups. This will be assessed by a self-paced 6 Minute 
Walk Test over a 60.96-metre (200 foot) circuit (38-40). Pain intensity will be measured 
before and after the walk test using a standardised pain scale for claudication (41). The 
walk test will be completed twice, with the highest 6MWD used for analysis. 
 
Secondary outcome measures 
Other measures will be used to assess the broader effects of the MOSAIC intervention.  
Maximal walking ability (duration walked before resting (seconds)) and pain free 
walking ability (duration walked before reported pain onset (seconds)) will be recorded 
during the 6 Minute Walk Test (42, 43). These parameters evaluate the global and 
integrated physiological responses of all systems involved with exercise and symptom 
manifestation. 
Self-reported Walking Distance (SR-MWD) will be measured by one global item: “What 
is the maximum distance (in metres) you can walk at your usual pace on a flat surface 
before leg pain forces you to stop?” (44) and the 4-item Walking Estimated-Limitation 
Calculated by History questionnaire (WELCH) (45, 46).  
Nottingham Extended Activities of Daily Living scale (NEADL) (47, 48) is a 22-item 
measure with 4 subscales (mobility, kitchen tasks, domestic tasks, leisure activities) and 
will assess function.  
The 6-item disease specific Vascular Quality of Life Questionnaire-6 (VascuQol-6) (49) 
and the EQ-5D-5L will assess quality of life (50).   
The 7-item Brief International Physical Activity Questionnaire (IPAQ) will estimate daily 
physical activity (35). 
Adverse events will be recorded by asking participants a single open-ended item: “Have 
you had any problems since your last assessment?” at three- and six-month follow-up. 
Trial physiotherapists will also report any adverse events in participants randomised to 
receive the MOSAIC intervention. 
 
14 
 
To determine the MCID, participants will provide a global rating of change score after 
five measures (6MWD, SR-MWD, WELCH, NEADL, VascuQoL-6) at the three-month and 
six-month follow-up assessments. In response to the question: “Has there been any 
change in your walking ability/walking distance/daily activities etc since the last test?” 
participants will be asked to rate their perceived change on a transitional three-point 
scale (1, worse; 2, about the same; 3, better). If they indicate no change, the participant 
will score 0. If they indicate there has been an improvement or deterioration, they will 
be asked to score their change on a 15-point Likert scale: (-7 = a very great deal worse 
to 7 = a very great deal better). Scores of -1, 0 and 1 will be considered no change, 
scores of 2–3 small improvement and scores of 4–7 substantial improvement (51, 52). 
 
Process variables 
Process variables will be collected to investigate the implementation and maintenance, 
unexpected pathways and consequences, and mechanisms of impact of MOSAIC.  
Attendance at MOSAIC sessions will be recorded by the trial physiotherapists. 
Adherence to walking goals will be assessed by the 6-item Exercise Adherence Rating 
Scale (EARS) (53, 54) at three and six-month follow-up.  
Fidelity to the MOSAIC intervention will be assessed in a random subset of ≥10% of the 
audio-recorded MOSAIC sessions/physiotherapist by two independent raters using 
bespoke, standardised checklists. 
The type and duration of usual care and non-NHS care received by both groups will be 
recorded using the modified Client Service Receipt Inventory (36)  to evaluate 
unexpected pathways and consequences.   
Proposed mechanisms of impact include changes to theoretically defined socio-
cognitive variables targeted by MOSAIC. The Brief Illness Perception Questionnaire (a 9 
item measure of individuals’ representation of their illness as defined by the Common-
Sense Model) (55), the Theory of Planned Behaviour Questionnaire (an 12 item 
measure of goals and beliefs about walking as treatment for intermittent claudication) 
(32) and the action planning and action control scale (a self-regulation questionnaire) 
(56, 57) will be assessed at each time point. 
 
Resource use variables 
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The study is an important opportunity to assess the feasibility of collecting data on 
resource use in adults with intermittent claudication to inform future trials. A modified 
Client Service Receipt Inventory (36) will be used to record information on service 
utilisation, income, accommodation and other cost-related variables at all time points to 
determine completion rates and redundant questions.  
Table 3 MOSAIC Trial Summary of Measures  
Measure Administered 
by 
Baseline 3 months  6 months 
Baseline measures  
Sociodemographic 
characteristics 
Self    
San Diego Claudication 
Questionnaire 
Self    
Ankle-Brachial Pressure 
Index 
Researcher    
Body Mass Index Researcher    
Primary Outcome 
6-Minute Walking Distance Researcher  X X  
Secondary Outcomes 
Pain-Free Walking Time Researcher X X  
Maximal Walking Time Researcher X X  
Self-Reported Maximal 
Walking Distance*  
Self X X X 
Walking Estimated-
Limitation Calculated by 
History 
Self X X X 
Nottingham Extended 
Activities of Daily Living 
scale 
Self X X X 
Vascular Quality Of Life-6*  Self X X X 
EQ-5D-5L  Self X X X 
Brief International Physical 
Activity Questionnaire*  
Self X X X 
Client Services Receipt 
Inventory 
Self X X X 
Process measures 
Brief Illness Perceptions 
Questionnaire 
Self X X X 
Theory of Planned 
Behaviour Questionnaire 
Self X X X 
Action Planning & Action 
Control 
Self X X X 
Exercise Adherence Rating 
Scale 
Self X X X 
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Measure Administered 
by 
Baseline 3 months  6 months 
Baseline measures  
Sociodemographic 
characteristics 
Self    
San Diego Claudication 
Questionnaire 
Self    
Ankle-Brachial Pressure 
Index 
Researcher    
Body Mass Index Researcher    
Adverse events* Self/ 
Physiotherapi
st/ Researcher 
 X X 
*Minimum dataset 
 
 
 
Qualitative study 
To explore the experience of MOSAIC treatment and participation in the trial, semi-
structured, audio-recorded interviews will be conducted with up to 30 participants or 
until data saturation of themes is reached. A purposive sampling strategy will ensure 
that a range of participants are selected (e.g. age, symptoms, group allocation, 
recruitment site). Interviews will be conducted via telephone or face-to-face (depending 
on participant preference) after completion of the final assessment. A subsample of 
physiotherapists will be interviewed to explore their experiences of training and 
delivering MOSAIC by an independent researcher, supported by experienced qualitative 
researchers in the trial team (12, 13, 58, 59). Interview schedules will be developed 
iteratively, and the questions asked may develop as insights from ongoing interviews 
and analyses reveal additional areas of relevance. Interviews will be transcribed 
verbatim, anonymised and analysed thematically by one researcher (60). The initial 
codes will be cross-referenced with a second researcher and the development of themes 
will be discussed with the trial team to provide different perspectives on coding. 
Themes will be presented to a sample of interviewees to ensure resonance and 
plausibility of the themes.   
Patient and Public Involvement 
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User involvement is central to the design and management of the MOSAIC trial. Patients 
were involved in the identification of the research question and two patient advisers 
reviewed the protocol and assisted in the development of all patient-related materials. 
One patient adviser is a funding co-applicant. Our patient advisers will be members of 
the trial management group, contribute to the trial physiotherapist training and 
dissemination. All participants will be invited to request study results, if interested. 
 
Data and statistical analysis plan 
Sample size 
Based on previous work (61), 192 participants will be required to detect a mean 6MWD 
difference of 58 metres (SD=111; α=0.05, 1-β=0.90), accounting for 20% attrition at 
three-month follow up.   
 
 
Statistical analysis 
A statistical analysis plan will be written by the trial statistician (SE) and agreed with 
the Trial Management Group and joint Trial Steering Committee/Data Monitoring and 
Ethics Committee. Analyses of primary and secondary outcomes and process variables 
will be conducted on an intention-to-treat basis and all included participants will be 
analysed as randomised.  
The primary outcome will be analysed using multiple regression and adjusted for 
baseline 6MWD and site. Results will be reported as the difference in mean 6MWD 
between the intervention and control groups with 95% confidence intervals. Other 
continuous outcomes and process variables will be similarly analysed. If appropriate, a 
mediation analysis using linear regression will examine mechanisms of impact.  
Descriptive statistics for sociodemographic and clinical characteristics, attendance at 
MOSAIC sessions, adherence to treatment and referral to or uptake of other treatments 
will be computed.  Adverse Events and Serious Adverse Events will be described. 
To determine the MCID, change scores for the five clinical measures will be calculated 
by subtracting the baseline result from the follow-up results for each participant. 
Correlations will be computed for participant self-assessment of performance scores 
and change in clinical outcomes. The mean change in scores for participants reporting 
no change, small improvement and substantial improvement will be compared by 
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ANOVA. The sensitivity and specificity for change in score to distinguish participants 
classified as changed (≥2) from those whose performance was unchanged (-1 to +1) will 
be calculated and a receiver operating characteristic curve obtained (62). The data 
point corresponding to the upper left corner of the curve will represent the MCID.  
As a sensitivity analysis, the MCID will be also calculated using a distribution-based 
approach. The standard error of measurement for all participants scores will be used to 
estimate the MCID based on the following equation: 𝜎1√(1 − 𝑟) where 𝜎1  is the baseline 
standard deviation and 𝑟 represents the intraclass correlation coefficient, which is a 
measure of the test-retest reliability of the scale. The intraclass correlation coefficient 
will be calculated using the baseline and follow-up scores for each participant. Using 
this method, one standard error of measurement represents the estimated MCID (63). 
If the proportion of missing data is above 10% multiple imputation will be considered 
as a sensitivity analysis for the primary outcome, and for the secondary outcomes used 
in the three and six month MCID (64).  
Data Management and Monitoring 
Data will be collected and retained in accordance with the Data Protection Act 1998, the 
General Data Protection Regulation 2016/679, and the Data Protection Policy of King's 
College London. Data for each participant will be identified by a unique identification 
number and entered onto a Food and Drug Administration compliant database system. 
Data will be stored separately from personal data to maintain confidentiality. The Chief 
Investigator will be the custodian of the data and the data will only be used by the trial 
team. 
The Trial Management Group is responsible for the management of the MOSAIC trial 
and is led by the Chief Investigator. It comprises trial investigators, a patient advisor 
and a vascular surgeon who meet regularly to discuss trial progress.  
A Trial Steering Committee/Data Monitoring and Ethics Committee provide study 
oversight. It is independently chaired and includes patient and public involvement 
representatives, independent, experienced physiotherapists, a psychologist and a 
statistician along with the Chief Investigator. It is independent of both the trial team and 
sponsors and operates under an agreed charter (MOSAIC Trial Steering 
Committee/Data Monitoring and Ethics Committee Charter v1.0 25 July 17). 
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Ethical considerations and dissemination 
Ethical Considerations 
The trial protocol was approved on 27th April 2017 by the London - Bloomsbury 
Research Ethics Committee (17/LO/0568). The Chief Investigator will submit and, if 
required, obtain approval from relevant parties for all substantial amendments to the 
original approved documents. The current protocol is Version 6 (approved on 28 
August 2018). 
The trial will be completed in accordance with the Declaration of Helsinki, the 
International Conference for Harmonisation of Good Clinical Practice guidelines and the 
Research Governance Framework for Health and Social Care.  
King’s College London and Guy’s and St Thomas’ NHS Foundation Trust 
(R&D@gstt.nhs.uk) are the trial sponsors and the lead site (Guy’s and St Thomas’ NHS 
Foundation Trust) will monitor and audit this project to ensure compliance with 
necessary legislation. 
All participants will provide written informed consent prior to any data collection.  
This is a low risk trial because MOSAIC is a non-invasive treatment which is delivered 
by trained, registered physiotherapists. Any adverse events will be recorded by the 
trained, trial physiotherapists and reported to the trial team. Participants will also be 
offered the opportunity to report any adverse events at follow-up assessments. Any 
serious adverse events will be referred to the Chief Investigator immediately.  
Dissemination 
Whilst the trial is in progress, we will disseminate trial updates via a dedicated website. 
(https://www.kcl.ac.uk/lsm/research/divisions/hscr/research/groups/Rehabilitation
/MOSAIC-Trial.aspx) and social media (http://blogs.kcl.ac.uk/mosaic/).  At the end of 
the trial, findings will be disseminated via patient forums, conferences presentations 
and peer reviewed publications. 
 
Trial status  
The trial was registered prospectively on 02/08/2017 (ISRCTN 14501418). The trial is 
funded to run for 36 months and commenced in July 2017. The first participant was 
randomised in January 2018 and recruitment for the trial is ongoing. The final follow-up 
visit for the final participant is projected to be completed by the end of month 34. 
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Conclusions 
The MOSAIC trial investigates the efficacy of a physiotherapist-led, theoretically-
informed, behaviour change intervention on walking ability compared to usual care in 
older adults with intermittent claudication.  It includes objective and self-reported 
measures of walking ability  but only follows participants for 6 months. The MOSAIC 
intervention addresses a gap in the recommended care pathway for management of 
intermittent claudication, where walking exercise is a first-line treatment. Future 
studies should investigate the effectiveness and cost effectiveness of MOSAIC. 
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Figure 1 MOSAIC Trial flowchart 
